Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-09-0020
European Journal of Endocrinology, Vol 161, Issue 2, 251-257
Copyright © 2009 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
EJE-09-0020v1
EJE-09-0020v2
161/2/251    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cleemann, L.
Right arrow Articles by Gravholt, C. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleemann, L.
Right arrow Articles by Gravholt, C. H

CLINICAL STUDY

Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome

Line Cleemann, Britta E Hjerrild1, Anna L Lauridsen2, Lene Heickendorff2, Jens S Christiansen1, Leif Mosekilde3 and Claus H Gravholt1

Pediatric Unit, Nordsjællands Hospital Hillerød, DK-3400 Hillerød, Denmark1 Medical Department M (Endocrinology and Diabetes) and the Medical Research Laboratories, Aarhus Sygehus NBG2 Department of Clinical Biochemistry, Aarhus Sygehus3 Department of Endocrinology and Metabolism, Aarhus Sygehus THG, Aarhus University Hospital, DK-8000 Aarhus C, Denmark

(Correspondence should be addressed to C H Gravholt; Email: ch.gravholt{at}dadlnet.dk)

Context: Reduced bone mineral density (BMD) and increased risk of fractures are present in many women with Turner syndrome (TS).

Objective: Examine longitudinal changes in BMD in TS and relate changes to biochemical parameters.

Design: Prospective, pragmatic, and observational study. Examinations at baseline and follow-up (5.9±0.7 years).

Setting: Tertiary hospital.

Participants: Fifty-four women with TS (43.0±9.95 years).

Interventions: Hormone replacement therapy (HRT) and calcium and vitamin D supplementation.

Main outcome measures: BMD (g/cm2) measured at lumbar spine, hip, and the non-dominant forearm. Bone formation and resorption markers, sex hormones, IGF1, and maximal oxygen uptake.

Results: At follow-up, forearm BMD, radius ultradistal BMD, and hip BMD remained unchanged, radius 1/3 BMD declined (0.601±0.059 vs 0.592±0.059, P=0.03), while spine BMD increased (0.972±0.139 vs 1.010±0.144, P<0.0005). Bone formation markers did not change over time in TS. Bone resorption markers decreased over time in TS. Testosterone, IGF1, and maximal oxygen uptake was significantly reduced in TS.

Conclusion: Longitudinal changes in BMD in TS were slight. BMD can be maintained at most sites in well-informed women with TS, being encouraged to maintain a healthy lifestyle, including HRT and intake of calcium and vitamin D.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 European Society of Endocrinology.